$509 Million is the total value of GREAT POINT PARTNERS LLC's 44 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CYTK | New | CYTOKINETICS INC | $17,595,000 | – | 500,000 | +100.0% | 3.46% | – |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $12,625,344 | – | 255,367 | +100.0% | 2.48% | – |
| RLAY | New | RELAY THERAPEUTICS INC | $10,839,352 | – | 658,127 | +100.0% | 2.13% | – |
| New | MINERALYS THERAPEUTICS INC | $9,714,305 | – | 620,326 | +100.0% | 1.91% | – | |
| New | ARCELLX INC | $7,918,355 | – | 257,006 | +100.0% | 1.56% | – | |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,214,200 | – | 380,000 | +100.0% | 0.83% | – |
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $3,810,590 | – | 70,371 | +100.0% | 0.75% | – |
| ETNB | New | 89BIO INC | $3,807,500 | – | 250,000 | +100.0% | 0.75% | – |
| ACRS | New | ACLARIS THERAPEUTICS INCcall | $2,022,500 | – | 250,000 | +100.0% | 0.40% | – |
| KMPH | New | ZEVRA THERAPEUTICS INC | $1,913,032 | – | 347,824 | +100.0% | 0.38% | – |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $1,740,185 | – | 97,544 | +100.0% | 0.34% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $1,644,333 | – | 2,032,550 | +100.0% | 0.32% | – |
| VKTX | New | VIKING THERAPEUTICS INCput | $1,332,000 | – | 80,000 | +100.0% | 0.26% | – |
| New | SOLID BIOSCIENCES INC | $997,320 | – | 210,405 | +100.0% | 0.20% | – | |
| New | AVALO THERAPEUTICS INC | $830,618 | – | 474,639 | +100.0% | 0.16% | – | |
| RPHM | New | RENEO PHARMACEUTICALS INC | $722,767 | – | 120,864 | +100.0% | 0.14% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.